Based on these preclinical data, the particularly high expression of IL18BP in ccRCC (12), and the demonstrated responsiveness of RCC to ICIs and other cytokine-based immunotherapies, we hypothesized that IL-18 could be an effective cytokine for treating aRCC. Here, IL18 is linked to renal cell carcinoma.